Sinovac Biotech

Sinovac Biotech Ltd. (, ) is a Chinese biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. The company is based in Haidian District, Beijing. The company is listed on the NASDAQ but the exchange halted Sinovac's trading in February 2019 due to a proxy fight.
Vaccines.
Sinovac's commercialized vaccines include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu (influenza), Panflu (H5N1) and PANFLU.1 (H1N1). Sinovac is currently developing a universal flu vaccine and a Japanese encephalitis vaccine.
Sinovac is also developing vaccines for enterovirus 71 and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.
COVID-19 vaccine development.
CoronaVac is an inactivated virus COVID-19 vaccine developed by Sinovac. It has been in Phase III clinical trials in Brazil, Chile, Indonesia, Philippines, and Turkey.
It relies on traditional technology similar to BBIBP-CorV and BBV152, other inactivated-virus COVID-19 vaccines in Phase III trials. CoronaVac does not need to be frozen, and both the vaccine and raw material for formulating the new doses could be transported and refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.
A real-world study of millions of Chileans who received CoronaVac found it 67% effective against symptoms, reduced hospitalizations by 85%, intensive care visits by 89%, and deaths by 80%. In Indonesia, real world data showed 94% of inoculated health care workers protected against symptomatic infection by the vaccine, beating results in clinical trials. Phase III results from Brazil had previously showed 50.7% efficacy at preventing symptomatic infections and 83.7% effective in preventing mild cases needing treatment. Final Phase III results from Turkey announced on 3 March 2021 showed an efficacy of 83.5%.
Politicization, transparency issues and some incomplete trial data in Brazil contributed to a lack of trust in CoronaVac there.
CoronaVac is being used in vaccination campaigns by certain countries in Asia, South America, North America, and Europe. In April, Sinovac had a production capacity of 2 billion doses a year and had delivered 300 million total doses. It is currently being manufactured at several facilities in China, with planned overseas manufacture in Brazil in September 2021 and eventually in Egypt.